And while human anecdotal and case reports are abundant, human clinical research remains limited, and we would ultimately like to see more well-designed human studies in the near future
GIP, or glucose-dependent insulinotropic polypeptide, is naturally produced in the gut and plays roles in nutrient absorption and intestinal function
The GLP-1 receptor agonists included dulaglutide (Trulicity, Eli Lilly), liraglutide (Saxenda, Novo Nordisk), exenatide (Bydureon, AstraZeneca), tirzepatide (Zepbound, Eli Lilly) and semaglutide
Key results included: Sustained improvements in skin quality, hydration, and radiance Over 88% of participants loved how treatment maintained their facial structure 9 out of 10 participants would recommend it after GLP-1 weight loss Visible improvements lasting up to 9 months Sculptra stimulates collagen and gradually improves laxity, while HA fillers restore immediate structure in areas that flatten with weight loss
Semaglutide is clinically indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as Type 2 diabetes, hypertension, high cholesterol, or cardiovascular disease
The concentration of Human VEGFA in the samples is then determined by comparing the OD of the samples to the standard curve